Ascendis Pharma - ASND Total Company Value-to-Revenue Ratio

Public company logo of Ascendis Pharma (ASND)

Demand for endocrine drugs is growing rapidly, as confirmed by the company's EV/Sales valuation, which currently stands around 11604.55. This chart highlights the success of the TransCon technology, which reduces injection frequency. The innovative long-acting ecosystem secures loyalty among patients with rare pathologies, providing Ascendis Pharma A/S (ASND) a sustainable advantage in metabolic therapy.

ASND Ascendis Pharma A/S: Enterprise Value-to-Revenue Ratio in the range 11/23/2025 - 11/20/2026

ASND (Ascendis): analytical breakdowns and indicator data

Fundamental company valuation:Ascendis Pharma A/S
Mass-produced product of Ascendis Pharma Inc.

For Ascendis Pharma A/S, the EV/Sales metric reflects the enterprise value of the business relative to its generated revenue stream. By analyzing the EV/Sales history, an investor sees the current ratio of 11604.55, which compares the actual sales of Skytrofa with the company's capitalization. The high value of this indicator confirms that the market has already priced in the future commercial success of new metabolic molecules.

Competitor analysis for Ascendis Pharma A/S

MDGL: Enterprise Value-to-Revenue Ratio|CORT: EV/Sales Multiple|RYTM - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Akero Corp|Metsera Therapeutics (MTSR) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio moonlaketx.com (MLTX)|Company Value to Revenue Crinetics Pharmaceuticals CRNX|Enterprise Value-to-Revenue Ratio NewAmsterdam Pharma N.V. NAMS|Total Company Value-to-Revenue Ratio Soleno Therapeutics Inc (SLNO)|FOLD - Enterprise Value-to-Revenue Ratio|ETNB: Enterprise Value-to-Revenue Ratio|AGIO: EV/Sales Multiple|Structure Therapeutics Inc. - Business Value to Revenue|MDXG (MiMedx Corp) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Rezolute Inc RZLT|EV/Sales Multiple LXRX|Total Company Value-to-Revenue Ratio MBX Corp|Altimmune Pharma - Company Value to Revenue|EV/Sales Multiple aardvarktherapeutics.com AARD|SGMT: Company Value to Revenue|Business Value to Revenue BIOA (BioAge Labs)|BMEA: EV/Sales Multiple|QNCX: Enterprise Value-to-Revenue Coefficient|GUTS (Fractyl Health, Inc.) - EV/Sales Multiple|EV/Sales Multiple vtvtherapeutics.com|Company Value to Revenue ATPC (Agape ATP Corp)|Total Company Value-to-Revenue Ratio Pluristem Therapeutics|Enterprise Value-to-Revenue Ratio synlogictx.com SYBX|LPCN: Company Value to Revenue Ratio|MTNB - Enterprise Value-to-Revenue Ratio|Spruce Biosciences, Inc. (SPRB) - Company Value to Revenue|GLTO: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Carmell Corp. (CTCX)|LUMO (Lumos Therapeutics) - EV/Sales Multiple|Organovo Corp (ONVO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Radius Recycling (RDUS)